Statin on insulin and adiponectin levels: true or false prophecy?

Venu Gopal Jonnalagadda¹
Afsar Shaik²

¹Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Bhangagarh, Guwahati, Assam, India; ²Department of Pharmacology, Narayana Pharmacy College, Chinthareddy Palem, Nellore, Andhra Pradesh, India

Dear editor

We read the article “Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction” by Gruzdeva et al¹ with interest. The authors conducted a prospective cohort study on patients with diagnosed myocardial infarction who were on different doses of atorvastatin, ie, 20 mg/d or 40 mg/d, for new onset of diabetes for a duration of 12 months.

In the results, the authors presented that (Table 2) the levels of insulin in group 1 (atorvastatin 20 mg/d) were 12.95 mU/mL (8.50; 14.60) on day 1 and 9.96 mU/mL (7.40; 12.70) at 1 year. In same vein, the levels of insulin in group 2 (atorvastatin 40 mg/d) were 12.5 mU/mL (8.90; 15.92) on day 1 and 12.67 mU/mL (9.74; 15.70) at 1 year. Moreover, the levels of adipokines (Table 3), ie, adiponectin, in group 1 (atorvastatin 20 mg/d) were 9.1 mg/mL (7.10; 12.40) on day 1 and 14.4 mg/mL (10.70; 17.00) at 1 year. In the case of group 2, the levels (atorvastatin 40 mg/d) were 8.7 mg/mL (5.50; 12.80) on day 1 and 10.6 mg/mL (7.40; 12.80) at 1 year.¹

After careful consideration, it can be understood that increased dose of statin did not affect insulin and adiponectin levels in a dose-dependent manner. In contrast to this, there were eight cases (20.5%) in the atorvastatin 40 mg/d group and one case (2.6%) in the atorvastatin 20 mg/d group diagnosed with new onset of diabetes out of 39 patients in each group.¹

In general, and accumulating data reiterates that, statins cause dose-dependent decrease in the levels of adiponectin and insulin and increase in the levels of glucose, ie, hyperglycemia. On the contrary, the authors presented that the levels of glucose increased along with insulin and adiponectin levels rather than decreased.²⁻⁴

We would be much obliged if you would kindly clarify these issues, and we also believe that managing cardiovascular events is important with statins after assessing the risk versus benefit ratio.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Gruzdeva O, Uchasova E, Dyleva Y, et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. *Diabetes Metab Syndr Obes*. 2017;10:481–489.
2. Sattar N, Taskinen MR. Statins are diabetogenic – myth or reality? *Atheroscler Suppl*. 2012;13:1–10.
3. Jonnalagadda VG, Choudhary K, Matety VK. Statins and new onset of diabetes: which one outweighs risk or benefit? *Postgrad Med*. 2018;130(1):146.
4. Maki KC, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. *Postgrad Med*. 2017;22:1–7.

Correspondence: Venu Gopal Jonnalagadda
Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Bhangagarh, Guwahati, Assam 781006, India
Tel +98 9258 8207
Email gopalvenu63@gmail.com

Authors' reply

Evgenya Uchasova
Olga Gruzdeva

Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation

Correspondence: Evgenya Uchasova
Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Disease, Laboratory of Research Homeostasis, 6 Sosnovy Boulevard, Kemerovo 650002, Russian Federation
Tel +7 384 2640 553
Fax +7 384 2643 410
Email evg.uchasova@yandex.ru

Dear editor

We would like to thank Venu Gopal Jonnalagadda and Afsar Shaik for the letter in response to our article.¹ Yes, indeed in our study, statins at a dose of 20 and 40 mg/mL, at 20 mg/d

atorvastatin, were observed to improve the sensitivity to insulin and eliminate adipokine imbalance and ghrelin deficiency. At a dose of 40 mg/d, atorvastatin showed increased negative effects, such as a reduction in insulin secretion, hyperglycemia, impaired glucose tolerance, high levels of leptin, ghrelin deficiency, and manifestation of type 2 diabetes mellitus. Statins at a dose of 80 mg/mL were not included in this work; however, at this dose in this study, we observed a decrease in levels of adiponectin and insulin.¹

Disclosure

The authors report no conflicts of interest in this communication.

Reference

1. Gruzdeva O, Uchasova E, Dyleva Y, et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. *Diabetes Metab Syndr Obes*. 2017;10:481–489.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert

opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>